An Open Pilot Study to Assess the Pharmacokinetics, Tolerability, and Safety of NEX-18a Given as a Subcutaneous Injection for the Treatment of Intermediate 2 or Higher-risk MDS, CMML or AML
Latest Information Update: 19 Oct 2023
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Nanexa
- 16 Oct 2023 Status changed from discontinued to completed.
- 04 Apr 2022 Status changed from recruiting to discontinued.
- 08 Sep 2021 New trial record